Lizet E. van der Kolk

Lizet E. van der Kolk

Auto-generated profile, based on publicly available information

Lizet E. van der Kolk

Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2021 in JMIR Research Protocols
Verified
Journal Article
Open access
LTLara Terra
Lara Terra
MHMaartje Hooning
Maartje Hooning
BHBernadette Heemskerk-Gerritsen
Bernadette Heemskerk-Gerritsen
MBMarc van Beurden
Marc van Beurden
JLJeanine elisabeth roeters Roeters van Lennep
Jeanine elisabeth roeters Roeters van Lennep
FLFlora E van Leeuwen
Flora E van Leeuwen
Background: BRCA1/2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) at 35 to 45 years of age. RRSO substantially decreases ovarian cancer risk, but at the cost of immediate menopause. Knowledge about the potential adverse effects of premenopausal RRSO, such as increased risk of cardiovascular disease, osteoporosis, cognitive dysfunction, and reduced health-related quality of life (HRQoL), is limited. Objective: The aim of this study is to assess the long-term health effects of premenopausal RRSO on cardiovascular disease, bone health, cognitive functioning, urological complaints, sexual functioning, and HRQoL in women with high familial risk of breast or ovarian cancer. Methods: We will conduct a multicenter cross-sectional study with prospective follow-up, nested in a nationwide cohort of women at high familial risk of breast or ovarian cancer. A total of 500 women who have undergone RRSO before 45 years of age, with a follow-up period of at least 10 years, will be compared with 250 women (frequency matched on current age) who have not undergone RRSO or who have undergone RRSO at over 55 years of age. Participants will complete an online questionnaire on lifestyle, medical history, cardiovascular risk factors, osteoporosis, cognitive function, urological complaints, and HRQoL. A full cardiovascular assessment and assessment of bone mineral density will be performed. Blood samples will be obtained for marker analysis. Cognitive functioning will be assessed objectively with an online neuropsychological test battery. Results: This study was approved by the institutional review board in July 2018. In February 2019, we included our first participant. As of November 2020, we had enrolled 364 participants in our study. Conclusions: Knowledge from this study will contribute to counseling women with a high familial risk of breast/ovarian cancer about the long-term health effects of premenopausal RRSO. The results can also be used to offer health recommendations after RRSO. Trial Registration: ClinicalTrials.gov NCT03835793; https://clinicaltrials.gov/ct2/show/NCT03835793. International Registered Report Identifier (IRRID): DERR1-10.2196/24414

27 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LLLina Helena Lankhorst
Lina Helena Lankhorst
HFHelle-Brit Fiebrich-Westra
Helle-Brit Fiebrich-Westra
IHIrene E.G. van Hellemond
Irene E.G. van Hellemond
NGNoor Giesbertz
Noor Giesbertz
LKLizet E. van der Kolk
Lizet E. van der Kolk
OHOlga Husson
Olga Husson
Purpose: Adolescents and young adults (AYAs; aged 18–39 years at cancer diagnosis) with poor-prognosis cancer may benefit from whole-genome sequencing (WGS) to optimise treatment selection and refine diagnosis. Given their distinct life phase, AYAs may have specific expectations, motivations, and information needs regarding WGS. This study explores AYAs' knowledge, expectations, motivations, and communication preferences prior to disclosure of WGS results.Methods: This study presents a cross-sectional analysis of baseline data from the longitudinal multicentre mixed-methods GEN-impact-AYA study, collected prior to disclosure of WGS results. Participants (N = 105) completed items assessing knowledge and expectations of WGS; factors influencing the decision to pursue WGS; attitudes toward WGS; perceived advantages and disadvantages; and satisfaction with WGS and the information provided.Results: Overall, AYAs were satisfied with their decision to have WGS. Main motivations included its potential to support treatment decisions (77.7%) and a desire to help future patients (53.4%). The majority (59.0%) had good knowledge of WGS. AYAs estimated, on average, a 60.5% probability that WGS would contribute to their diagnosis or treatment, on a scale from 0 (very unlikely) to 100% (very likely). However, many AYAs reported receiving limited information on the likelihood of treatment implications and potential germline findings.Conclusion: AYAs with poor-prognosis cancer receiving paired tumour–normal WGS recognise its potential to guide treatment decisions and contribute to future care. However, their expectations often reflect hope and may exceed the realistic clinical yield of WGS. Clinicians should clearly communicate tumour-specific implications of WGS, including potential germline findings. Given the high information-seeking behaviour among AYAs, directing them to trustworthy (online) resources before disclosure of WGS results is essential.